Novel approaches to the discovery of antimicrobial agents

Current Opinion in Chemical Biology

Volumn 2, Issue 4, 1998, Pages 529-534

  Schmid, Molly B ^a  

^a Microcide Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

BACTERIAL GENE; BACTERIAL GENOME; DNA SEQUENCE; DRUG SCREENING; ESSENTIAL GENE; REVIEW;

ANTI-INFECTIVE AGENTS; DRUG EVALUATION, PRECLINICAL; GENES, BACTERIAL; GENES, ESSENTIAL; GENOME, BACTERIAL; SEQUENCE ANALYSIS, DNA;

EID: 0032134269     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(98)80130-0     Document Type: Article

References (60)

1. Levy SB: The challenge of antibiotic resistance. Sci Am 1998, March:46-53.
2. Ford CW, Hamel JC, Stapert D, Moerman JK, Hutchinson DK, Barbachyn MR, Zurenko GE: Oxazolidinones: new antibacterial agents. Trends Microbiol 1997, 5:196-200.
3. Baquero F: Gram-positive resistance: challenge for the development of new antibiotics. J Antimicrob Chemother 1997, 39(suppl A):1-6.
4. Fraise AP, Andrews J, Wise R: Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms. J Antimicrob Chemother 1997, 40:423-425.
5. Nissen-Meyer J, Nés IF: Ribosomally synthesized antimicrobial peptides: their function, structure, biogenesis, and mechanism of action. Arch Microbiol 1997, 167:67-77.
6. Joshi N, Miller DQ: Doxycycline revisited. Arch Intern Med 1997, 157:1421-1428.
7. Nicas TI, Mullen DL, Flokowitsch JE, Preston DA, Snyder NJ, Zweifel MJ, Wilkie SC, Rodriguez MJ, Thompson RC, Cooper RD: Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci. Antimicrob Agents Chemother 1996, 40:2194-2199.
8. Bouanchaud DH: In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin. J Antimicrob Chemother 1997, 39(suppl A):15-21.
9. Bush K: Antimicrobial agents. Curr Opin Chem Biol 1997, 1:169-175.
10. Malabarba A: New approaches to the treatment of vancomycin-resistant bacterial infections. Exp Opin Ther Patents 1996, 6:627-644.
11. Hancock REW: Peptide antibiotics. Lancet 1997, 349:418-422.
12. Blattner FR, Plunkett G III, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhgew GF et al.: The complete genome sequence of Escherichia coli K-12. Science 1997, 277:1453-1474. This describes the genome sequence of Escherichia coli, with an excellent discussion of the features of the genome and comparison with other genome sequences.
13. Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, Bult CJ, Tomb J-F, Dougherty BA, Merrick JM et al.: Whole-genome random sequencing and assembly of Haemophilus influenzae rd. Science 1995, 269:496-512.
14. Fraser CM, Gocayne JD, White O, Adams MD, Clayton RA, Fleishmann RD, Bult CJ, Kerlavage AR, Sutton G, Kelley JM et al.: The minimal gene complement of Mycoplasme genitalium. Science 1995, 270:397-403.
15. Fraser CM, Casjens S, Huang WM, Sutton GG, Clayton R, Lathigra R, White O, Ketchum KA, Dodson R, Mickey EK et al.: Genomic sequence of a lyme disease spirochaete, Borrelia burgdorferi. Nature 1997, 390:580-586. The DNA sequence of B. burgdorferi is notable for its linear chromosome and 17 plasmids.
16. Kunst F, Ogasawara N, Mosner I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessieres P, Bolotin A, Borchert S et al.: The complete genome sequence of the Gram-positive bacterium Bacillus subtilis. Nature 1997, 390:249-256. The DNA sequence of the best-characterized gram-positive bacterium.
17. Smit DR, Richterich P, Rubenfield M, Rice PW, Butler C, Lee HM, Kirst S, Gundersen K, Abendschan K, Xu Q et al.: Multiplex sequencing of 1.5 Mb of the Mycobacterium leprae genome. Genome Res 1997, 7:802-19.
18. Tomb JF, White O, Kerlavage AR, Clayton RA, Sutton GG, Fleischmann RD, Ketchum RA, Klenk HP, Gill S, Dougherty BA et al.: The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 1997, 388:539-547. The DNA sequence of an important human pathogen is described, with a focus on the unique metabolism that Helicobacter pylori must have to survive in acidic conditions.
19. Fraser CM, Fleischmann RD: Strategies for whole microbial genome sequencing and analysis. Electrophoresis 1997, 18:1207-1216. An excellent review of the technical issues of sequencing and annotation of microbial genomes, methods for gene expression analysis and DNA microarrays.
20. Mushegian A, Koonin E: A minimal gene set for cellular life derived by comparison of complete bacterial genomes. Proc Natl Acad Sci USA 1996, 93:10268-10273.
21. Posfai G, Blattner F, Kirkpatrick H, Koob M: Versatile insertion plasmids for targeted genome manipulations in bacteria: isolation, depletion, and rescue of the pathogenicity island LEE of the Escherichia coli O157:H7 genome. J Bacteriol 1997, 179:4426-4428.
22. Bergthorsson U, Ochman H: Distribution of chromosome length variation in natural isolates of Escherichia coli. Mol Biol Evol 1998, 1:6-16.
23. Lee C: Pathogenicity islands and the evolution of bacterial pathogens. Infect Agents Dis 1996, 1:1-7.
24. Karaolis D, Reeves P, Kaper J, Boedeker E, Bailey C, Johnson J: A Vibrio cholerae pathogenicity island associated with epidemic and pandemic strains. Proc Natl Acad Sci USA 1998, 95:3134-3139.
25. McDaniel TK, Jarvis KG, Donnenberg MS, Kaper JB: A genetic locus of enterocyte effacement conserved among diverse enterobacterial pathogens. Proc Natl Acad Sci USA 1995, 92:1664-1668.
26. Himmelreich R, Hilbert H, Plagens H, Pirkl E, Li B-C, Herrmann R: Complete sequence analysis of the genome of the bacterium Mycoplasma pneumoniae. Nucleic Acids Res 1996, 24:4420-4449.
27. Barrett JF, Goldschmidt RM, Lawrence LE, Foleno B, Chen R, Demers JP, Johnson S, Kanojia R, Fernandez J, Bernstein J et al.: Antibacterial agents that inhibit two-component signal transduction systems. Proc Natl Acad Sci USA 1998, 95:5317-5322. Novel antibacterial agents that inhibit bacterial histidine protein kinase activity are described.
28. Desnottes JF: New targets and strategies for the development of antibacterial agents. Trends Biotechnol 1996, 14:134-140.
29. Link A, Phillips D, Church G: Methods for generating precise deletions and insertions in the genome of wildtype Escherichia coli: application to open reading frame characterization. J Bacteriol 1997, 179:6228-6237. A novel method for producing nonpolar deletions in E. coli. A general review of methods of bacterial gene disruption is provided, including many potential complications of using other disruption methods.
30. Smith V, Chou K, Lashkari D, Botstein D, Brown PO: Functional analysis of the genes of yeast Chromosome V by genetic footprinting. Science 1996, 274:2069-2074.
31. Harris SD, Cheng J, Pugh TA, Pringle JR: Molecular analysis of Saccharomyces cerevisiae chromosome I. On the number of genes and the identification of essential genes using temperature-sensitive lethal mutations. J Mol Biol 1992, 225:53-65.
32. Bostian KA, Schmid MB: New antibacterial targets and new approaches for drug discovery. In Antibacterial Therapy: Achievements, Problems and Future Perspectives. Edited by Busse WD, Zeiler HJ, Labischinski H. Berlin: Springer-Verlag; 1997:61-68. A description of various novel genetic approaches to antibacterial drug discovery.
33. Schmid MB, Kapur N, Isaacson DR, Lindroos P, Sharpe C: Genetic analysis of temperature-sensitive lethal mutants of Salmonella typhimurium. Genetics 1989, 123:625-633.
34. Maniloff J: The minimal cell genome: on being the right size. Proc Natl Acad Sci USA 1996, 93:10004-10006.
35. Koonin EV: Genome sequences: genome sequence of a model prokaryote. Curr Biol 1997, 7:R656-R659.
36. Koonin EV, Mushegian AR, Bork P: Non-orthologous gene displacement Trends Genet 1996, 12:334-336.
37. Isaacson RE: Novel targets for antibiotics: an update. Exp Opin Invest Drugs 1997, 6:1009-1017.
38. Davies JE: Origins, acquisition and dissemination of antibiotic resistance determinants. Ciba Found Symp 1997, 207:1-27.
39. Van Veen HW, Konings WN: Drug efflux proteins in multidrug resistant bacteria. Biol Chem 1997, 378:769-777.
40. Davies J, Wright GD: Bacterial resistance to aminoglycoside antibiotics. Trends Microbiol 1997, 5:233-240.
41. Brakstad OG, Maeland JA: Mechanisms of methicillin resistance in staphylococci. APMIS 1997, 105:264-276.
42. Heithoff DM, Conner CP, Mahan MJ: Dissecting the biology of a pathogen during infection. Trends Microbiol 1997, 5:50913.
43. Chee M, Yang R, Hubbell E, Berno A, Huang XC, Stern D, Winkler J, Lockhart D, Morris MS, Fodor SPA: Accessing genetic information with high-density DNA arrays. Science 1996, 274:610-614.
44. Baumler AJ, Kusters JG, Stojiljkovic I, Heffron F: Salmonella typhimurium loci involved in survival within macrophages. Infect Immun 1994, 62:162330.
45. Chiang SL, Mekalanos JJ: Use of signature-tagged transposon mutagenesis to identify Vibrio cholerae genes critical for colonization. Mol Microbiol 1998, 27:797-805.
46. Mei JM, Nourbakhsh F, Ford CW, Holden DW: Identification of Staphylococcus aureus virulence genes in a murine model of bacteraemia using signature-tagged mutagenesis. Mol Microbiol 1997, 26:399-407. Pools of molecularly tagged bacterial strains allow more efficient screening for mutants that fail to grow in vivo.
47. Umezawa H: Low-molecular-weight enzyme inhibitors of microbial origin. Annu Rev Microbiol 1982, 36:75-99.
48. Tomoda H, Omura S: New strategy for discovery of enzyme inhibitors: screening with intact mammalian cells or intact microorganisms having special functions. J Antibiot (Tokyo) 1990, 43:1207-1223.
49. Ramsay G: DNA chips: state-of-the-art. Nat Biotechnol 1998, 16:40-44.
50. DeRisi JL, Vishwanath RI, Brown PO: Exploring the metabolic and genetic control of gene expression on a genomic scale. Science 1997, 278:680-686. The 6000 open reading frames of Saccharomyces cerevisiae are used for microarray-based gene expression studies. Gene expression is monitored during glucose limitation, and during the underexpression and overexpression of specific transcription factors.
51. Lashkari DA, DeRisi JL, McCusker JH, Namath AF, Gentile C, Hwang SY, Brown PO, Davis RW: Yeast microarrays for genome wide parallel genetic and gene expression analysis. Proc Natl Acad Sci USA 1997, 94:13057-13062. Technical aspects of gene expression microarrays in Saccharomyces cerevisiae, as well as comparisons of genes expressed during heat-shock, coldshock, and glucose and galactose growth. Many genes are differentially expressed under these conditions.
52. Marshall A, Hodgson J: DNA chips: an array of possibilities. Nat Biotechnol 1998, 16:27-31.
53. Wodicka L, Lockhart DJ, Ho MH, Mittmann M, Dong H: Genome- wide expression monitoring in Saccharomyces cerevisiae. Nat Biotechnol 1997, 15:1359-1367. Gene expression microarrays in Saccharomyces cerevisiae, using arrays of oligonucleotides. Comparisons of mRNAs synthesized in rich and minimal medium are presented.
54. De Saizieu A, Certa U, Warrington J, Gray C, Keck W, Mous J: Bacterial transcript imaging by hybridization of total RNA to oligonucleotide arrays. Nat Biotechnol 1998, 16:45-48. Results of gene expression microarrays in Streptococcus pneumonias and Haemophilus influenzae. Assays of oligonucleotide arrays and psoralen-biotin labeling of RNA were performed. Genes expressed during the development of competence, and during exponential and stationary phase were examined in S. pneumoniae.
55. Chuang SE, Daniels DL, Blattner FR: Global regulation of gene expression in Escherichia coli. J Bacteriol 1993, 175:2026-2036. Using lambda clones of E. coli DNA, gene expression during a variety of growth conditions was monitored.
56. Major J: Challenges and opportunities in high throughput screening: implications for new technologies. J Biomol Screening 1998, 3:13-17.
57. Oldenburg KR, Zhang J, Chen T, Maffia III A, Blom KF, Combs AP, Chung DY: Assay miniaturization for ultra-high throughput screening of combinatorial and discrete compound libraries: a 9600-well (0.2 microliter) assay system. J Biomol Screening 1998, 3:55-62.
58. Rodrigues DA: Preclinical drug metabolism in the age of high-throughput screening: an industrial perspective. Pharmacol Res 1997, 14:1504-1510.
59. Breckenridge A: A clinical pharmacologist's view of drug toxicity. Br J Clin Pharmacol 1996, 42:53-58.
60. Bains W: Company strategies for useful bioinformatics. Trends Biotechnol 1996, 4:312-317.